Blood transfusion and coagulation management

Meier, Jens

doi:10.1016/j.bpa.2016.06.002

Cited by 6 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood transfusion is an indispensable part of modern medicine in supporting numerous clinical therapies [ 48 , 49 , 50 ]. However, the complete procedure from blood collection to administration faces a number of concerns and challenges to overcome that need to be addressed [ 51 , 52 ].…”

Section: Ex Vivo Generation Of Developing Erythrocytesmentioning

confidence: 99%

Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome

Detzner

Pohlentz

Müthing

2020

Toxins

View full text Add to dashboard Cite

The global emergence of clinical diseases caused by enterohemorrhagic Escherichia coli (EHEC) is an issue of great concern. EHEC release Shiga toxins (Stxs) as their key virulence factors, and investigations on the cell-damaging mechanisms toward target cells are inevitable for the development of novel mitigation strategies. Stx-mediated hemolytic uremic syndrome (HUS), characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal injury, is the most severe outcome of an EHEC infection. Hemolytic anemia during HUS is defined as the loss of erythrocytes by mechanical disruption when passing through narrowed microvessels. The formation of thrombi in the microvasculature is considered an indirect effect of Stx-mediated injury mainly of the renal microvascular endothelial cells, resulting in obstructions of vessels. In this review, we summarize and discuss recent data providing evidence that HUS-associated hemolytic anemia may arise not only from intravascular rupture of erythrocytes, but also from the extravascular impairment of erythropoiesis, the development of red blood cells in the bone marrow, via direct Stx-mediated damage of maturing erythrocytes, leading to “non-hemolytic” anemia.

show abstract

Section: Ex Vivo Generation Of Developing Erythrocytesmentioning

confidence: 99%

Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome

Detzner

Pohlentz

Müthing

2020

Toxins

View full text Add to dashboard Cite

show abstract

“…Patient blood management (PBM) aims to optimize the transfusion of LBPs (restrictive strategy), develop alternatives and improve the quality of patient care, achieving a primary prevention of transfusion risks (5,6). PBM actions may concern the training, organisation, use of treatments, therapeutic or diagnostic devices, which are the subject of recommendations and consensus conferences (7)(8)(9). A recent meta-analysis on the effective cost of PBM in surgery shows a reduction in complications and postoperative mortality allowing, despite an additional cost linked to PBM, an overall reduction in the costs of care (10,11).…”

Section: Resultsmentioning

confidence: 99%

Cost of red blood cell transfusion; evaluation in a French academic hospital

Rigal¹,

Riche²,

Tching-Sin³

et al. 2020

Transfusion Clinique et Biologique

View full text Add to dashboard Cite

“…The use of blood products is also closely related to coagulation function (Madisetty J, Wang C, 2017;Meier J, 2016;Kozek-Langenecker SA, 2014;Yoon U, et al, 2022). Massive transfusion (MT) is an effective method for treating hemorrhagic shock.…”

Section: Coagulation and Sepsismentioning

confidence: 99%

Coagulation Function Testing Clinical Demand and Current Status in China

Li,

Chen,

Zhang

et al. 2024

JIMR

View full text Add to dashboard Cite

Diseases or symptoms related to coagulation function are widely present in clinical daily work, as coagulation function plays a central role in maintaining homeostasis in the internal environment. Therefore, coagulation dysfunction often leads to serious harm to patients. At the same time, coagulation related treatments such as the use of anticoagulants or transfusion therapy have potential serious side effects, even leading to patient death. For many years, balancing the bleeding or embolism caused by anticoagulants has been a challenge that clinical workers have to face, which poses great challenges to clinical work. Therefore, monitoring coagulation function is very important for clinical diagnosis and treatment. The rapid and accurate completion of coagulation function diagnosis conclusions and early transmission to clinical workers are important guarantees for patient life. However, at present, due to technical limitations and the complexity of the detection process, this demand cannot be met. At present, in China, coagulation function testing is mostly concentrated in laboratory departments, and the limitation of distance may affect the timeliness of coagulation function testing. Therefore, many clinical departments of institutions tend to conduct coagulation function testing themselves, which has led to many new demands for coagulation function testing, such as fast and convenient POCT coagulation function testing and coagulation function testing of cell models that are more in line with clinical needs, More joint detection of coagulation markers and so on, of course, these needs must be established on the premise that clinical testing equipment and laboratory testing results are consistent. However, in order to meet the needs of miniaturization and rapid testing, the coagulation function testing equipment used in clinical departments often has significant methodological differences from laboratory testing equipment, which further leads to differences in testing results. Based on this situation, many new technologies, including microfluidic technology, as well as more detection techniques, have been widely and deeply applied to clinical coagulation function testing, which has brought a lot of good news to clinical coagulation function diagnosis to a large extent.

show abstract

Blood transfusion and coagulation management

Cited by 6 publications

References 55 publications

Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome

Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome

Cost of red blood cell transfusion; evaluation in a French academic hospital

Coagulation Function Testing Clinical Demand and Current Status in China

Contact Info

Product

Resources

About